ABT-100

Name: ABT-100
Brand: TargetMol
SKU: T10223
Price: 173 USD
Availability: InStock
Rating: 4.5 (1 reviews)

还可以

产品编号 T10223Cas号 450839-40-4

ABT-100 is a potent, highly selective, and orally active farnesyl transferase inhibitor with broad-spectrum antitumor activity.

还可以

产品编号 T10223Cas号 450839-40-4

ABT-100 is a potent, highly selective, and orally active farnesyl transferase inhibitor with broad-spectrum antitumor activity.

大包装 & 定制

加入购物车

该分子属于定制产品。TargetMol拥有优秀的合成团队，经验和能力，可以为您提供高性价比的产品。但由于客观因素，研发中会存在小概率合成不成功的情况，还请理解，如您有任何问题，欢迎咨询，我们将竭诚为您服务。

实验操作小课堂

联系我们获取更多批次信息

资源下载

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性

产品描述	ABT-100 is a potent, highly selective, and orally active farnesyl transferase inhibitor with broad-spectrum antitumor activity.
体外活性	ABT-100 (0.1-100 nM; 7 days; EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells) treatment shows dose-dependent growth inhibition of human cancer cell lines. It also inhibits colony formation at concentrations comparable with which ABT-100 inhibits anchorage-dependent growth. ABT-100 inhibits cell proliferation (IC50s of 2.2 nM, 3.8 nM, 5.9 nM, 6.9 nM, 9.2 nM, 70 nM and 818 nM for EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells, respectively), increases apoptosis and decreases angiogenesis.
体内活性	ABT-100 (6.25-12.5 mg/kg/day; subcutaneous injection; daily; for 21 days; C.B-17 scid male mice) treatment regresses EJ-1 tumors in mice.
细胞实验	Cell Line: EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells. Concentration: 0.1-100 nM. Incubation Time: 7 days
动物实验	Animal Model: C.B-17 scid male mice with EJ-1 cells. Dosage: 6.25 mg/kg/day, 12.5 mg/kg/day. Administration: Subcutaneous injection; daily; for 21 days